FIELD: medicine, pharmaceutics.
SUBSTANCE: application of alpha-1-antitrypsin (AAT) for preparing a drug for treating chronic fatigue syndrome (CFS) is offered. It is shown: AAT inhibited intracellular elastase activity of mononuclear cells of peripheral blood of the CFS patients, prevented degradation RNAase L 83 kDa with formation of the overactive RNAase L 37 kDa form. After treating with the preparation AAT, elastase activity in the specified blood cells decreased from approximately 1459 U/mg to 134 U/mg; the patient showed obvious clinical improvements, decreased cognitive disorders cognitive infringements, has went back to work. Particularly, the invention refers to the application of plasma or other therapeutic forms containing alpha-1-antitrypsin sufficient for produce a dosage of alpha-1-antitrypsin equal to 6 mg or more per one kg of body weight with frequency 1 to 31 days.
EFFECT: higher clinical effectiveness.
4 cl
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC TECHNIQUE FOR ASTHENIC SYNDROME IN SCHIZOPHRENIC PATIENTS | 2019 |
|
RU2709105C1 |
| TREATMENT AND/OR PREVENTION OF DISEASE OR SYNDROME ASSOCIATED WITH VIRAL INFECTION | 2021 |
|
RU2823437C2 |
| METHODS OF PRODUCING AND USING RECOMBINANT ALPHA-1-ANTITRYPSIN (AAT) AND COMPOSITIONS BASED THEREON | 2020 |
|
RU2817416C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF LUNG EMPHYSEMA AND OTHER FORMS OF COPD | 2019 |
|
RU2789128C2 |
| METHOD OF PREDICTIVE DIAGNOSTICS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2022 |
|
RU2814535C1 |
| FUSION SERPINE POLYPEPTIDES AND METHODS FOR THEIR APPLICATION | 2012 |
|
RU2642310C2 |
| ALPHA-1-ANTITRYPSIN FOR TREATING EPISODES OF PULMONARY DISEASE AGGRAVATIONS | 2007 |
|
RU2472524C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2727452C1 |
| METHOD FOR EARLY DETECTION OF NEUROLOGICAL DISORDERS IN PATIENTS WITH COVID-19 | 2021 |
|
RU2779562C1 |
| METHOD FOR PREVENTION OF AGGRAVATED RECURRENT RHINOSINUSITIS | 2013 |
|
RU2562537C2 |
